Skip to main
OCUL
OCUL logo

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Ocular Therapeutix (OCUL) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocular Therapeutix Inc. demonstrates a positive outlook due to significant revisions in its peak risk-adjusted sales estimates for its pipeline product, AXPAXLI, which has been raised from $1.9 billion to $3.2 billion, reflecting increased confidence in its Phase 3 programs for wet AMD and NPDR. The company's investment in research and development, with expenses climbing to $52.4 million from $37.1 million year-over-year, suggests a commitment to advancing its clinical programs, particularly through the SOL-X data that may enhance patient retention and market opportunities. Additionally, the stable patient base indicated by management, along with improved forecasts for other products in the pipeline, further supports the potential for strong financial performance in the future.

Bears say

Ocular Therapeutix Inc. reported a decline in net revenue for the quarter, falling to $14.5 million from $15.4 million a year prior, indicating potential challenges in sustaining revenue growth. The company has continuously incurred substantial losses since its inception, raising concerns about its long-term financial viability. Additionally, significant market competition and uncertainties surrounding the clinical performance of its products, particularly with the potential risks associated with Axpaxli, could adversely affect Ocular's market penetration and pricing strategies.

Ocular Therapeutix (OCUL) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocular Therapeutix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocular Therapeutix (OCUL) Forecast

Analysts have given Ocular Therapeutix (OCUL) a Buy based on their latest research and market trends.

According to 10 analysts, Ocular Therapeutix (OCUL) has a Buy consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocular Therapeutix (OCUL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.